

Hepatic decompensating events in patients with type 2 diabetes
(Comparison between propensity–score matched cohorts: Combinations vs monotherapy)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)	# of cases (overall risk) (Comparison cohort)	HR (95% CI)
GLP–1RA(+)DRUG(+) vs DRUG(+)GLP–1RA(–)					
91,421	GLP–1RA(+)Insulin(+)	Insulin(+)GLP–1RA(–)	2,704 (2.96%)	3,749 (4.10%)	0.63 (0.60–0.67)
77,794	GLP–1RA(+)Metformin(+)	Metformin(+)GLP–1RA(–)	1,505 (1.94%)	1,836 (2.36%)	0.75 (0.70–0.81)
23,646	GLP–1RA(+)DDP–4(+)	DPP–4(+)GLP–1RA(–)	563 (2.38%)	713 (3.02%)	0.69 (0.61–0.77)
41,689	GLP–1RA(+)SGLT2(+)	SGLT2(+)GLP–1RA(–)	806 (1.93%)	1,007 (2.42%)	0.66 (0.60–0.73)
46,620	GLP–1RA(+)SU(+)	SU(+)GLP–1RA(–)	962 (2.06%)	1,318 (2.83%)	0.65 (0.60–0.71)
17,763	GLP–1RA(+)TZD(+)	TZD(+)GLP–1RA(–)	301 (1.70%)	370 (2.08%)	0.72 (0.62–0.84)
GLP–1RA(+)DRUG(+) vs GLP–1RA(+)DRUG(–)					
44,939	GLP–1RA(+)Insulin(+)	GLP–1RA(+)Insulin(–)	1,054 (2.34%)	291 (0.65%)	3.22 (2.83–3.67)
44,617	GLP–1RA(+)Metformin(+)	GLP–1RA(+)Metformin(–)	1,165 (2.61%)	1,202 (2.69%)	0.86 (0.79–0.93)
32,119	GLP–1RA(+)DDP–4(+)	GLP–1RA(+)DPP–4(–)	763 (2.38%)	673 (2.10%)	1.06 (0.95–1.17)
59,969	GLP–1RA(+)SGLT2(+)	GLP–1RA(+)SGLT2(–)	1,221 (2.04%)	1,413 (2.36%)	0.76 (0.70–0.82)
49,408	GLP–1RA(+)SU(+)	GLP–1RA(+)SU(–)	1,071 (2.17%)	1,092 (2.21%)	0.90 (0.82–0.98)
19,297	GLP–1RA(+)TZD(+)	GLP–1RA(+)TZD(–)	331 (1.72%)	388 (2.01%)	0.80 (0.69–0.93)

0.20 0.300.40 0.600.80 2.0 3.00 4.0

Hazard Ratio (HR)